Easterbrook P J, Rostron T, Ives N, Troop M, Gazzard B G, Rowland-Jones S L
Dept. of HIV Medicine, Weston Education Centre, The Guy's, King's, London SE5 9RT, United Kingdom.
J Infect Dis. 1999 Oct;180(4):1096-105. doi: 10.1086/314997.
The role of polymorphisms in genes encoding chemokines and their receptors (CCR2B, SDF-1, and the promoter region of CCR5) in human immunodeficiency virus (HIV) disease progression was studied in 132 white HIV type 1 (HIV-1)-infected participants from a United Kingdom cohort study. Genotyping was done by use of amplification refractory mutation system-polymerase chain reaction with sequence-specific primers, and Cox proportional hazards models were used to examine the impact of polymorphisms on time to a CD4 cell count <200x106/L and to CDC stage IV disease. The results confirm a significant association of the CCR2B-64I mutant genotype with slower progression to a CD4 count <200 (hazards ratio [HR], 0.39; 95% confidence interval [CI], 0.17-0.91) but not with the SDF-1alpha 3' UTR homozygous mutation. The effects of the CCR5 and CCR2 mutations were genetically independent and similar in the magnitude of their protective effect on progression to a CD4 count <200 cells. A novel finding was an association of borderline significance between homozygosity for C at nucleotide position 59353 in the CCR5 promoter region and a slower rate of CD4 cell decline to <200x106/L (HR, 0. 58; 95% CI, 0.34-0.996).
在一项来自英国队列研究的132名感染1型人类免疫缺陷病毒(HIV-1)的白人参与者中,研究了趋化因子及其受体(CCR2B、SDF-1以及CCR5启动子区域)编码基因中的多态性在HIV疾病进展中的作用。采用序列特异性引物的扩增阻滞突变系统-聚合酶链反应进行基因分型,并使用Cox比例风险模型来检验多态性对CD4细胞计数<200×10⁶/L以及美国疾病控制与预防中心(CDC)IV期疾病发生时间的影响。结果证实,CCR2B - 64I突变基因型与进展至CD4计数<200的速度较慢显著相关(风险比[HR],0.39;95%置信区间[CI],0.17 - 0.91),但与SDF - 1α 3' UTR纯合突变无关。CCR5和CCR2突变的影响在基因上是独立的,并且在对进展至CD4计数<200个细胞的保护作用大小方面相似。一个新发现是,CCR5启动子区域核苷酸位置59353处的C纯合性与CD4细胞下降至<200×10⁶/L的速度较慢之间存在边缘显著性关联(HR,0.58;95% CI,0.34 - 0.996)。